Acadia Pharmaceuticals ACAD Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's change in accrued liabilities?
- Acadia Pharmaceuticals (ACAD) reported change in accrued liabilities of $23.56M in Q1 2026.
- How has Acadia Pharmaceuticals's change in accrued liabilities changed year-over-year?
- Acadia Pharmaceuticals's change in accrued liabilities increased by 20407.8% year-over-year, from -$116K to $23.56M.
- What is the long-term trend for Acadia Pharmaceuticals's change in accrued liabilities?
- Over 2 years (2023 to 2025), Acadia Pharmaceuticals's change in accrued liabilities has grown at a -54.5% compound annual growth rate (CAGR), from $93.17M to -$19.27M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.